Nano‐Theranostic Modality for Visualization of the Placenta and Photo‐Hyperthermia for Potential Management of Ectopic Pregnancy
Source abstract
Abstract
Abstract Ectopic pregnancy (EP) is the leading cause of maternity‐related death in the first trimester of pregnancy. Approximately 98% of ectopic implantations occur in the fallopian tube, and expedient management is crucial for preventing hemorrhage and maternal death in the event of tubal rupture. Current ultrasound strategies misdiagnose EP in up to 40% of cases, and the failure rate of methotrexate treatment for confirmed EP exceeds 10%. Here the first theranostic strategy for potential management of EP is reported using a near‐infrared naphthalocyanine dye encapsulated within polymeric nanoparticles. These nanoparticles preferentially accumulate in the developing murine placenta within 24 h following systemic administration, and enable visualization of implantation sites at various gestational stages via fluorescence and photoacoustic imaging. These nanoparticles do not traverse the placental barrier to the fetus or impact fetal development. However, excitation of nanoparticles localized in specific placentas with focused NIR light generates heat (>43 °C) sufficient for disruption of placental function, resulting in the demise of targeted fetuses with no effect on adjacent fetuses. This novel approach would enable diagnostic confirmation of EP when current imaging strategies are unsuccessful, and elimination of EP could subsequently be achieved using the same nano‐agent to generate localized hyperthermia resulting in targeted placental impairment.
Source: crossref · Quality: baseline
Research context
OpenAlex topics: Photoacoustic and Ultrasonic Imaging · Ultrasound and Hyperthermia Applications · Nanoplatforms for cancer theranostics
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Department of Pharmaceutical Sciences College of Pharmacy Oregon State University 2730 S Moody Avenue Portland OR 97201 USA
Department of Obstetrics and Gynecology School of Medicine Oregon Health and Science University 3181 SW Sam Jackson Park Road Portland OR 97239 USA
Department of Pathology and Laboratory Medicine School of Medicine Oregon Health and Science University 3181 SW Sam Jackson Park Road Portland OR 97239 USA
Funding
Eunice Kennedy Shriver National Institute of Child Health and Human Development
References (51)
Show source-provided references
1. 10.1016/j.fertnstert.2010.09.00610.1016/j.fertnstert.2010.09.006 ↗
2. 10.1097/AOG.000000000000156810.1097/AOG.0000000000001568 ↗
3. Taran F. A. · Dtsch. Arztebl. · 2015 · 112 · 693
4. T.Tulandi UpToDate (accessed October 2022).
5. 10.1016/S0015-0282(00)01761-110.1016/S0015-0282(00)01761-1 ↗
6. Barnhart K. T. · Obstet. Gynecol. · 2002 · 100 · 505
7. 10.1148/radiol.245206103110.1148/radiol.2452061031 ↗
8. 10.1097/GRF.0b013e3182510a7310.1097/GRF.0b013e3182510a73 ↗
9. 10.1016/j.addr.2020.09.00610.1016/j.addr.2020.09.006 ↗
10. 10.1210/en.2012-183210.1210/en.2012-1832 ↗
11. 10.1126/sciadv.160034910.1126/sciadv.1600349 ↗
12. 10.7150/thno.2290410.7150/thno.22904 ↗
13. 10.1146/annurev-bioeng-071811-15012410.1146/annurev-bioeng-071811-150124 ↗
14. 10.1016/j.placenta.2017.03.00110.1016/j.placenta.2017.03.001 ↗
15. 10.1016/j.addr.2022.11423810.1016/j.addr.2022.114238 ↗
16. 10.1093/molehr/gau08410.1093/molehr/gau084 ↗
17. 10.1016/j.pacs.2019.10014410.1016/j.pacs.2019.100144 ↗
18. 10.1098/rsfs.2011.002810.1098/rsfs.2011.0028 ↗
19. 10.1038/srep3513710.1038/srep35137 ↗
20. 10.1016/j.pacs.2018.05.00110.1016/j.pacs.2018.05.001 ↗
21. 10.1177/153601211880272110.1177/1536012118802721 ↗
22. 10.1039/C6CS00765A10.1039/C6CS00765A ↗
23. 10.1038/nmeth.148310.1038/nmeth.1483 ↗
24. 10.14366/usg.1406210.14366/usg.14062 ↗
25. 10.1063/1.219502410.1063/1.2195024 ↗
26. 10.1039/C7TB02573D10.1039/C7TB02573D ↗
27. 10.1016/j.als.2016.11.00410.1016/j.als.2016.11.004 ↗
28. 10.3390/pharmaceutics1207063010.3390/pharmaceutics12070630 ↗
29. 10.1016/j.nantod.2019.10079510.1016/j.nantod.2019.100795 ↗
30. 10.7150/thno.2120910.7150/thno.21209 ↗
31. 10.3390/pharmaceutics1211102010.3390/pharmaceutics12111020 ↗
32. 10.1002/smll.20190693610.1002/smll.201906936 ↗
33. 10.1016/j.actbio.2021.07.01510.1016/j.actbio.2021.07.015 ↗
34. 10.1186/s12951-018-0392-810.1186/s12951-018-0392-8 ↗
35. 10.1038/nmeth.392910.1038/nmeth.3929 ↗
36. 10.1242/dev.16342810.1242/dev.163428 ↗
37. 10.1016/j.jmmm.2013.11.00610.1016/j.jmmm.2013.11.006 ↗
38. 10.1016/j.addr.2011.03.00810.1016/j.addr.2011.03.008 ↗
39. 10.1530/rep.1.0060610.1530/rep.1.00606 ↗
40. 10.1039/D0TB00612B10.1039/D0TB00612B ↗
41. 10.1016/S0303-7207(01)00703-110.1016/S0303-7207(01)00703-1 ↗
42. 10.1097/00004347-198706000-0000510.1097/00004347-198706000-00005 ↗
43. 10.1093/humupd/dmg04310.1093/humupd/dmg043 ↗
44. 10.3389/fendo.2018.0057010.3389/fendo.2018.00570 ↗
45. 10.1095/biolreprod.116.14068110.1095/biolreprod.116.140681 ↗
46. CD‐1 Mice Growth Chart https://www.criver.com/products-services/find-model/cd-1r-igs-mouse?region=3611(accessed August 2022).
47. 10.1016/0143-4004(95)90000-410.1016/0143-4004(95)90000-4 ↗
48. 10.1021/acs.chemmater.5b0312810.1021/acs.chemmater.5b03128 ↗
49. 10.1016/j.nano.2016.11.00510.1016/j.nano.2016.11.005 ↗
50. 10.1021/acs.molpharmaceut.6b0020510.1021/acs.molpharmaceut.6b00205 ↗
51. Croy A. · 2013